Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of PXT3003 in CMT1A
NCT03023540Phase 3Active, not recruiting
- Sponsor
- Pharnext
- Start
- Mar 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Pharnext. Started Mar 2017; status: active, not recruiting.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT03023540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023540.